NGF Mutein Production Process Patent Application
Summary
Chiesi Farmaceutici SpA filed USPTO patent application US20260092090A1 on April 2, 2026, for a process producing nerve growth factor (NGF) and muteins at high purity from recombinant sources. The muteins may exhibit improved detectability and reduced nociceptive activity compared to wildtype human NGF. Application No. 19265384 was filed July 10, 2025.
What changed
Chiesi Farmaceutici SpA published patent application US20260092090A1 disclosing a process for producing nerve growth factor (NGF) and muteins thereof, particularly human NGF muteins, at high purity from recombinant sources. The application (No. 19265384) names Bruno Pietro Imbimbo as inventor and claims muteins characterized by improved detectability and/or reduced nociceptive activity relative to wildtype human NGF.
This publication establishes a priority date of July 10, 2025. Competitors developing NGF-based therapeutics or production processes should review this application for potential freedom-to-operate implications. No compliance deadlines or regulatory actions are required at this stage; the application remains pending and will be examined by the USPTO.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PRODUCTION OF NERVE GROWTH FACTOR (NGF) AND OF MUTEINS THEREOF
Application US20260092090A1 Kind: A1 Apr 02, 2026
Assignee
Chiesi Farmaceutici SpA
Inventors
Bruno Pietro Imbimbo
Abstract
The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and/or reduced nociceptive activity, compared to wildtype human NGF.
CPC Classifications
C07K 14/48 C07K 1/165 C12N 9/6427 A61K 38/00
Filing Date
2025-07-10
Application No.
19265384
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.